Published in Drug Week, January 7th, 2005
Nautilus has designed and developed an improved, single amino-acid substitution, non-pegylated interferon alpha (Belerofon) with superior biological and pharmacological profile compared to marketed pegylated interferon alpha. Belerofon is a product candidate for a number of indications including chronic hepatits C and cancer. Its improved profile should support lower frequency of administration and lower dosing with higher therapeutic efficacy.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.